The Liver Meeting
The Liver Meeting
November 11, 2019
2 min watch

VIDEO: Shorter duration Mavyret safe, effective in all HCV genotypes

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

BOSTON — In this exclusive video from The Liver Meeting 2019, Robert S. Brown Jr., MD, MPH, of Weill Cornell Medical College, discusses the results of the EXPEDITION-8 trial, which demonstrated that treatment with Mavyret over 8 weeks was effective and had a favorable safety profile in patients with treatment-naive chronic hepatitis C virus genotypes 1-6 and compensated cirrhosis.

“We know we have a plethora of medications to choose [from] with hepatitis C, but the new recommendations from our organizations are to choose a pangenotypic therapy that is safe and effective,” Brown told Healio Gastroenterology and Liver Disease. “Having a simple regimen is also critical if we’re going to achieve the WHO goals of HCV elimination by 2030.”

The majority (97.7%, n = 335/343) of patients with genotypes 1-6 in the intent-to-treat population achieved SVR12 with glecaprevir/pibrentasvir (Mavyret, AbbVie).

More than half (63%) of the reported adverse events were grade 1 in severity. The most commonly reported side effects included fatigue (9%), pruritus (8%) and headache (8%).

“This allows us to treat all of our patients regardless of fibrosis stage with a shorter 8-week regimen,” he said. “Of course, it’s important to remember that glecaprevir/pibrentasvir is only approved for use in patients with compensated cirrhosis. It is contraindicated in moderate-to-severe hepatic impairment.”

Reference: Brown RS. LP9. Presented at: The Liver Meeting; Nov. 7-12, 2019; Boston.

Disclosure: Brown reports serving as a consultant for AbbVie, Bristol-Myers Squibb, Dova, Gilead, Intercept, Merck and Shionogi. Brown also reports receiving grant/research support from AbbVie, Bristol-Myers Squibb, Gilead, Intercept and Merck.